Storm shows PoC for RNA epigenetic inhibitor as field moves toward clinic

Storm Therapeutics unveiled what it called the first in vivo proof-of-concept data for a small molecule inhibitor of an RNA epigenetic enzyme. Data were presented Wednesday at

Read the full 272 word article

User Sign In